ReviewFrontiers in chemistry2026
Carbon dots in cancer therapy: a novel approach to targeted drug delivery and reduced toxicity in gallbladder cancer.
Review in Frontiers in chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biliary tract cancers (BTCs), including cholangiocarcinoma and gallbladder carcinoma, are highly aggressive malignancies associated with poor prognosis, late diagnosis, and limited therapeutic options. Conventional chemotherapy offers only modest survival benefits because of inadequate tumor selectivity, rapid systemic clearance, dose-limiting toxicity, and the emergence of chemoresistance. Carbon quantum dots (CQDs) have emerged as promising nanotheranostic agents owing to their ultrasmall size, tunable photoluminescence, excellent aqueous dispersibility, biocompatibility, and versatile surface chemistry, enabling simultaneous drug delivery, imaging, and phototherapy. This review summarizes the evolution of carbon dots into structurally engineered CQDs and discusses their physicochemical, optical, and biological properties that underpin their biomedical applications. Particular emphasis is placed on recent advances in CQD-based drug delivery, fluorescence bioimaging, photothermal therapy, photodynamic therapy, and multifunctional theranostic platforms relevant to BTC management. Although direct studies on CQDs for BTC remain limited, emerging evidence from hepatobiliary and other gastrointestinal cancers highlights their potential to improve targeted drug delivery, tumor imaging, and therapeutic efficacy. The review further identifies critical challenges to clinical translation, including the lack of BTC-specific preclinical models, insufficient pharmacokinetic and long-term biosafety data, and the need for standardized, reproducible CQD synthesis and functionalization protocols. Finally, future research directions are discussed, emphasizing tumor-targeted CQD engineering, multimodal therapeutic strategies, and integration with precision oncology. Collectively, CQDs represent a promising nanoplatform for the development of targeted, image-guided, and minimally invasive approaches for the diagnosis and treatment of biliary tract cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.